source
- Moderna-Merck mRNA cancer vaccine shows landmark interim success in melanoma trialAn interim analysis of a Phase 3 trial of an individualized mRNA cancer vaccine from Moderna and Merck showed the treatment met its primary goals. The vaccine, given together with Merck's immunothe…
- Merck and Moderna report personalized mRNA vaccine delays melanoma recurrence in late-stage trialMerck and Moderna announced that a personalized mRNA cancer vaccine, when combined with standard therapy, slowed the return of melanoma and reduced its spread in a late-stage clinical study. The tr…